Editas Medicine, Inc. (Nasdaq: EDIT), a clinical stage genome
editing company, today announced the appointment of current
Independent Director Emma Reeve as Chair of the Board, effective at
the Company’s next annual stockholder meeting, currently scheduled
for June 1. Ms. Reeve will be replacing James C. Mullen as he steps
down from the Board and his role as Executive Chair. The Company
also announced the appointment of Elliott Levy, M.D., to its Board
of Directors as an independent director.
“I am eager to work with Emma in her new capacity as Chair of
the Board and to welcome Elliott to our Board,” said Gilmore
O’Neill, M.B., M.M.Sc., President and Chief Executive Officer,
Editas Medicine. “Emma has made significant contributions to Editas
in the past 18 months on our Board, including chairing our audit
committee and providing sound oversight on our recent iNK portfolio
divestiture and strategic reprioritization. Elliot is an
accomplished drug development executive, and his work has led to a
number of new medicines. This significant experience and expertise
will be an asset to our drug development efforts as we work to
develop and commercialize transformative gene editing medicines.
Together, along with the rest of our esteemed Board members, I know
Emma and Elliott will make significant contributions to Editas in
their Board service,” said Dr. O’Neill.
Emma Reeve joined the Editas Medicine Board of Directors in
September 2021. Ms. Reeve is an accomplished biopharmaceutical
executive with more than 25 years of global financial experience
across pharmaceutical, medical device, and biopharma companies.
“I am thrilled to take on this new role as Chair of the Editas
Board of Directors and to partner with the Board and management as
the Company executes its new strategy and transitions into a
commercial company,” said Ms. Reeve.
Dr. Levy is an accomplished biopharmaceutical executive with
more than 20 years of global research and development expertise,
including leading clinical strategy and development for multiple
programs at all stages of development at global biopharmaceutical
companies Amgen and Bristol Myers Squibb.
“Editas Medicine is at the forefront of developing medicines
that will dramatically alter the treatment paradigm of difficult to
treat diseases, and I am excited to join their Board of Directors.
I look forward to working with the team as they advance their
ground-breaking medicines to and through the clinic and
commercialization to improve the lives of people living with
serious diseases,” said Dr. Levy.
Dr. O’Neill added, “I would also like to thank Jim for his
tremendous service to Editas over the past five years, both as our
former CEO and as the longtime Chair of our Board. His leadership
and experience greatly served our Company and drove us towards our
ultimate goal of helping people living with serious diseases. We
will miss him at Editas, and we wish him well in his new
endeavor.”
About Emma ReeveMost recently, Ms. Reeve served
as Chief Financial Officer of Constellation Pharmaceuticals, Inc.,
a development-stage oncology company, prior to its acquisition by
MorphoSys AG in 2021. Ms. Reeve led Constellation’s IPO in 2018.
Prior to Constellation, Ms. Reeve acted as interim Chief Financial
Officer and Corporate Controller of Parexel International, a global
biopharmaceutical services company, where she was responsible for
all aspects of finance, investor relations, procurement, and
facilities. In this role, she led the finance aspects of a
sell-side process which culminated in an agreement to take the
company private in a $5 billion leveraged buy-out. Earlier in her
career, Ms. Reeve served as Chief Financial Officer of both Inotek
Pharmaceuticals and Aton Pharma. Additionally, she held senior
finance and operational roles at Bristol Myers Squibb, Merck, and
Novartis.
Ms. Reeve serves on the Board of Directors of PTC Therapeutics,
Inc., Ribon Therapeutics, and Aadi Bioscience, Inc. She also serves
on the Board of Trustees for Tufts Medical Center. Ms. Reeve holds
a B.Sc. in computer science from Imperial College, University of
London and is an associate of the Institute of Chartered
Accountants in England & Wales.
About Elliott Levy, M.D.Dr. Levy served as
Senior Vice President and Head of Global Development and R&D
Strategy and Operations at Amgen from 2014-2021. Prior to Amgen, he
was a Senior Vice President at Bristol Myers Squibb, where he held
various R&D positions of increasing responsibility during his
17-year tenure at the company.
Dr. Levy currently serves on the Board of Omega Therapeutics,
Inc. and NuCana plc, both public biotechnology companies. In
addition, he is a Venture Partner at 5AM Venture Management, LLC,
and is a co-founder and former Chief Executive Officer of the
Intrepid Alliance, an industry-led non-profit consortium whose
objective is to accelerate the development of small molecule
therapeutics for potential viral pandemic agents. Dr. Levy received
his B.A. in History from Yale College and an M.D. from the Yale
School of Medicine, where he also completed fellowship training in
internal medicine, nephrology, and clinical research.
About Editas MedicineAs a
clinical stage genome editing company, Editas Medicine is focused
on translating the power and potential of the CRISPR/Cas9 and
CRISPR/Cas12a genome editing systems into a robust pipeline of
treatments for people living with serious diseases around the
world. Editas Medicine aims to discover, develop, manufacture, and
commercialize transformative, durable, precision genomic medicines
for a broad class of diseases. Editas Medicine is the exclusive
licensee of Broad Institute and Harvard University’s Cas9 patent
estates and Broad Institute’s Cas12a patent estate for human
medicines. For the latest information and scientific presentations,
please visit www.editasmedicine.com.
Forward-Looking Statements This press release
contains forward-looking statements and information within the
meaning of The Private Securities Litigation Reform Act of 1995.
The words ‘‘anticipate,’’ ‘‘believe,’’ ‘‘continue,’’ ‘‘could,’’
‘‘estimate,’’ ‘‘expect,’’ ‘‘intend,’’ ‘‘may,’’ ‘‘plan,’’
‘‘potential,’’ ‘‘predict,’’ ‘‘project,’’ ‘‘target,’’ ‘‘should,’’
‘‘would,’’ and similar expressions are intended to identify
forward-looking statements, although not all forward-looking
statements contain these identifying words. The Company may not
actually achieve the plans, intentions, or expectations disclosed
in these forward-looking statements, and you should not place undue
reliance on these forward-looking statements. Actual results or
events could differ materially from the plans, intentions and
expectations disclosed in these forward-looking statements as a
result of various factors, including: uncertainties inherent in the
initiation and completion of preclinical studies and clinical
trials and clinical development of the Company’s product
candidates; availability and timing of results from preclinical
studies and clinical trials; whether interim results from a
clinical trial will be predictive of the final results of the trial
or the results of future trials; expectations for regulatory
approvals to conduct trials or to market products and availability
of funding sufficient for the Company’s foreseeable and
unforeseeable operating expenses and capital expenditure
requirements. These and other risks are described in greater detail
under the caption “Risk Factors” included in the Company’s most
recent Annual Report on Form 10-K, which is on file with the
Securities and Exchange Commission, and in other filings that
the Company may make with the Securities and Exchange Commission in
the future. Any forward-looking statements contained in this press
release speak only as of the date hereof, and the Company expressly
disclaims any obligation to update any forward-looking statements,
whether because of new information, future events or otherwise.
Photos accompanying this announcement are available
at:https://www.globenewswire.com/NewsRoom/AttachmentNg/686528ee-c6da-40e5-ad36-692621376a39https://www.globenewswire.com/NewsRoom/AttachmentNg/7a6c77fa-8933-4a79-90d4-4bed5819f390
Media and Investor Contact:
Cristi Barnett
(617) 401-0113
cristi.barnett@editasmed.com
Editas Medicine (NASDAQ:EDIT)
Historical Stock Chart
From Jul 2024 to Jul 2024
Editas Medicine (NASDAQ:EDIT)
Historical Stock Chart
From Jul 2023 to Jul 2024